2015年11月23日

主制药完成收购印度制药11/23/15主Pharmaceuticals Inc . (OTCQB: PVOTF),一个新兴的生物技术公司从事疗法的发展以满足未满足的医疗需求在妇女健康,高兴地宣布,该公司已完成收购印度制药公司此前宣布11月5日,2015年。交易的财务条款没有披露。此外,主的董事会已经任命普拉文·查图尔维迪博士为其新任首席执行官和董事。查图尔维迪博士是印度制药公司的创始人兼董事长兼联合创始人Oceanyx药品。在+ 25年的职业生涯在制药行业,查图尔维迪博士参加了几个新药物的成功开发和商业化,目前各个公司的销售。他曾担任总裁和首席执行官的接穗制药和顶点药品领导评估主管。他曾在临床前组Alkermes公司和产品开发小组Parke-Davis /华纳兰波特公司(现在辉瑞)。查图尔维迪博士持有西弗吉尼亚大学制药科学博士学位和学士在药房孟买大学的乔治敦大学医学院兼职教员。主席艾哈迈德博士Doroudian主说,“我们非常高兴获得印度河和期待查图尔维迪博士的领导下继续发展改变生活的药对女性健康的未满足的需求。查图尔维迪博士是一个成功的商业领袖和科学家将大大加快主的发展和主股东带来巨大的价值。 " Dr. Pravin Chaturvedi added, "I look forward to leading Pivot as we bring new therapies through the clinic to address unmet or underserved needs in women's health and gynecological cancers. The combined resources of Pivot and IndUS present a unique opportunity for us to build a strong, successful, research-driven company that will focus on women's health, gynecological cancers, oral mucositis and diabetes. We are reviewing our clinical programs and evaluating the priorities for various programs to ensure accelerated development and faster time to market. IndUS also has an existing partnership with the Indian Institute of Chemical Technology (IICT), a Council of Scientific and Industrial Research (CSIR) institution, which provides an advantage to the Pivot-IndUS group to accelerate new therapies for treatment of women's cancers such as metastatic endometrial and triple-negative breast cancers. Pivot intends to initiate human clinical trials with at least one development candid ate by the end of Q4 2016. " In conjunction with the closing of the IndUS transaction, Pivot also announces that Dr. B.J. Bormann has resigned as CEO and Director of Pivot. Pivot's Board would like to thank Dr. Bormann for her many contributions to the Company and wish her well in her future endeavors. About Pivot Pharmaceuticals Inc. Pivot is an early stage biopharmaceutical company engaged in the development of therapeutic pharmaceutical products, with a strategic emphasis on the innovation of new therapeutic uses for existing drugs to treat unmet or underserved conditions related to women's health including cancer. Pivot has identified novel candidates for the treatment of gynecological disturbances such as dysmenorrhea and menopausal symptoms (hot flashes), as well as kidney stones and lower urinary tract symptoms (LUTS) in women. About IndUS Pharmaceuticals Inc. IndUS Pharmaceuticals Inc. is a privately-held US-India cross-border pharmaceutical company focused on the discovery and development of a sustainable pipeline of innovative and novel drugs for the treatment of cancer, infectious diseases and diabetes. IndUS has exclusive rights to certain intellectual property from the Indian Institute of Chemical Technology, a Council of Scientific and Industrial Research (CSIR) institute, which is coupled with IndUS' biology and clinical development expertise in the United States, allowing accelerated drug development of novel therapeutics for global markets. Stories you Need to Know Stories you Need to Know It's on us. Share your news here.